| Publications | PubMed=29686424; DOI=10.1038/s41591-018-0007-9; PMCID=PMC5964608
Jacqulyne P. Robichaux, Yasir Yousif Elamin, Zhi Tan, Brett W. Carter, Shu-Xing Zhang, Sheng-Wu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal, Anh T. Le ...Show all 24 authors... , Anna Truini, Monique B. Nilsson, Hui-Ying Sun, Emily Roarty, Sarah B. Goldberg, Julie Renee Brahmer, Mehmet Altan, Charles Lu, Vassiliki Papadimitrakopoulou, Katerina Politi, Robert C. Doebele, Kwok-Kin Wong, John Victor Heymach; Show fewer authors
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Nat. Med. 24:638-646(2018) PubMed=35820397; DOI=10.1016/j.ccell.2022.06.006; PMCID=PMC9667883
Yasir Yousif Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don Lynn Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiu-Ning Le, Marcelo Vailati Negrao ...Show all 27 authors... , Monique B. Nilsson, Anisha Patel, Ramaswamy S.K. Vijayan, Jason B. Cross, Jian-Jun Zhang, Lauren Averett Byers, Charles Lu, Tina Cascone, Lei Feng, Rajyalakshmi Luthra, Francis Anthony San Lucas, Geeta Mantha, Mark J. Routbort, George R. Blumenschein Jr., Anne S. Tsao, John Victor Heymach; Show fewer authors
Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Cancer Cell 40:754-767.e6(2022) |
|---|
